Oleogel S10

Drug Profile

Oleogel S10

Alternative Names: AP 101; Betulin-based oleogel; Episalvan; Oleogel-S10; Sericare

Latest Information Update: 01 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Birken GmbH
  • Developer Amryt Pharma
  • Class Herbal medicines; Skin disorder therapies; Triterpenes
  • Mechanism of Action Keratinocyte modulators; Transient receptor potential channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Wounds
  • Phase III Burns; Epidermolysis bullosa
  • Phase II Actinic keratosis

Most Recent Events

  • 29 Mar 2017 Phase-III clinical trials in Epidermolysis bullosa (In adolescents, In children, In the elderly, In adults) in Spain (Topical) (EudraCT2016-002066-32)
  • 29 Mar 2017 Phase-III clinical trials in Epidermolysis bullosa (In children, In adolescents, In adults, In the elderly) in Australia (Topical) (NCT03068780)
  • 09 Dec 2016 Birken AG has been acquired by Amryt Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top